MO - Altria Group Inc Stock Price Quote - NYSE | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Investor

Is it the right time to buy or sell?

Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Altria Reports In-Line Fourth Quarter; Shares Fairly Valued

Director Philip Gorham

Philip Gorham, CFA, FRM Director

Business Strategy and Outlook

| Philip Gorham, CFA, FRM | May 3, 2022

Altria is no longer a pure play on U.S. cigarettes. Over 15% of our valuation is derived from its 10.2% share of Anheuser-Busch InBev, and of the consolidated business, 14% of EBIT came from oral tobacco in 2021, while recent acquisitions in vaping and cannabis are likely to be contributors to EBIT in the near future. Nevertheless, U.S. cigarettes remains the driver of Altria's earnings, because following the breakup of Philip Morris in 2008, Altria operates solely in the U.S., while Philip Morris International, or PMI, owns the rights to the brands elsewhere.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MO

Company Profile MO

Business Description

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

Contact

6601 West Broad Street
Richmond, VA, 23230

T +1 804 274-2200

Sector Consumer Defensive

Industry Tobacco

Most Recent Earnings Jun 30, 2022

Fiscal Year End Dec 31, 2022

Employees 6,000

Related News MO

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks

A majority of the top 10 dividend-yielding names are undervalued.

Verushka Shetty

Stock Analyst Update

Final Nail in the Coffin for Altria’s Juul Investment, but FDA Ban Has Little Impact on Our Valuation

We have long been skeptics of Juul’s outlook.

Turbulent Markets Spark ETF Outflows in April

U.S. ETFs endure their first month of outflows since 2019 as stocks and bonds both retreat.

What’s Really Inside Equity ESG Portfolios?

Any stock you can think of is on the menu.

ETF Flows Cool Off as Stocks Stumble Out of the Gate

Tepid ETF flows accompanied turbulent markets in January.

Will Cannabis Stocks Revive in 2022?

There's plenty of opportunity for these stocks after a rough 2021.

Kristoffer Inton

13 Good Companies Run by Poor Capital Allocators

These firms all have wide and narrow economic moats but earn poor capital allocation ratings.

Susan Dziubinski

Stock Analyst Update

Impressive Margins for Altria but Volumes Slip in Q3

Consolidated net revenue fell by 2.6% year over year, driven by a steep 12.9% decline in smokeable segment volume. We had expected a sequential volume deterioration from the adjusted decline of 4.5% in the second quarter, due to trade inventory movements, but this was disappointing relative to our expectations of flat net revenue. However, price/mix of 10.3% and the 90 basis point year-over-year improvement in gross margin to 66.4% were both impressive, and suggest that the competitive environment became less promotional during the quarter.

The Week Ahead: Facebook, Apple, and Amazon.com to Report Earnings

Other big names, including Coca-Cola, Ford, and Exxon Mobil, will be reporting, too.

Carole Hodorowicz

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks

A majority of the top 10 dividend-yielding names are undervalued.

Malik Ahmed Khan

Stock Analyst Update

Altria’s Q2 Shows Tobacco Is a Commodity Safe Haven

We retain our fair value estimate.

The Week Ahead: Tesla, General Electric, and Facebook to Report Earnings

A long list of companies across several sectors will report.

Carole Hodorowicz

Stock Strategist Industry Reports

Still a Long Road to Legalizing Cannabis Federally

But investors can still find value in U.S. cannabis stocks.

Kristoffer Inton

Digging into Oakmark Fund's Portfolio

The fund is a stalwart exemplar of patient, value-driven management.

Stock Analyst Update

FDA Announces Plan to Ban Menthol

We plan to lower our tobacco valuations by mid-single-digit amounts.

The Week Ahead: Tesla, Microsoft, Boeing, Altria Group, and AbbVie to Report Earnings

The week ahead is packed with earnings reports from companies across all sectors.

Carole Hodorowicz

Stock Analyst Update

Rumors of Menthol, Nicotine Bans Are Risks, But Not New

We maintain our valuations and wide moat and negative trend ratings for the cigarette makers as reports have surfaced that the Biden administration is considering lowering the nicotine and menthol levels in cigarettes.

Stock Analyst Update

Robust Altria Q4 Increases Our Conviction in Valuation

Altria reported another robust performance at the top line in the fourth quarter of 2020. Although we are not changing our $54 fair value estimate, this performance increases our conviction that Altria is undervalued.

The Week Ahead: Apple, Facebook, and Tesla to Report Earnings

The week ahead is stacked with big names across every sector.

Carole Hodorowicz

Stock Strategist Industry Reports

What E&Ps Can Learn From Big Tobacco

Here's a playbook for exploration and production companies to restore investor confidence.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.